In approved clinical trials, storage of investigational medicinal products (IMPs) must follow the trial sponsor's validated, written procedures and must take place in authorised pharmacy or laboratory facilities using qualified, alarmed, temperature-monitored equipment
1c) but no difference in CNR2 (Fig
Kalathil stresses, This momentum presents both opportunity and urgency for pharmaceutical and device manufacturers to ensure delivery systems can keep pace with demand while maintaining safety, sustainability, and regulatory integrity. The complexity of these devices, often involving multilayer packaging, elastomeric seals, and polymeric components, also heightens the need for robust analytical validation
Meanwhile, newer mechanisms, including muscle-preserving combinations and multi-agonist approaches, are being explored to differentiate future entrants and address limitations such as lean mass loss
doi: 10.1053/j.ajkd.2013.10.057
Some may experience more pronounced laxative effects, leading to diarrhea, cramping, or electrolyte disturbances
